戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 he presence of the pharmacological chaperone astemizole.
2    Treatment of hindlimb-suspended mice with astemizole, a known Merg1a channel blocker, inhibits atr
3 ive histamine1 (H1) receptor antagonist drug astemizole, a widely prescribed antihistamine.
4 imilar findings were obtained with the drugs astemizole and cisapride, as well as with high concentra
5 tro ATPase assays confirmed three (ebastine, astemizole and clotrimazole) out of seven tested candida
6  drugs approved for human use and identified astemizole and tacrolimus, which reduced cell-surface Pr
7                           The metabolites of astemizole and those of other antihistamine compounds ha
8 ethylastemizole, the principal metabolite of astemizole, blocks delayed rectifier potassium (K+) chan
9                                              Astemizole, but not tacrolimus, prolonged the survival t
10 Cytochrome P450 3A4 metabolizes terfenadine, astemizole, carbamazepine, alprazolam, triazolam, and ot
11  phenotype cells and was inactive in a [(3)H]astemizole competitive binding assay for hERG liability
12 exposure of NRVMs to LUF7244 or LUF7244 plus astemizole did not affect their viability, excitability,
13 mperature for R752W or with the hERG blocker astemizole for G601S dissociates channel-chaperone compl
14 ts and the favorable drug characteristics of astemizole, including its ability to cross the blood-bra
15 n and torsade de pointes are associated with astemizole intake and have been ascribed to block the re
16 olongation and torsade de pointes found with astemizole intake may principally be caused by the proar
17                                              Astemizole is used in humans to treat seasonal allergic
18 nt with undetectable serum concentrations of astemizole (< 0.5 ng/ml) and "therapeutic" concentration
19               Desmethylastemizole, the major astemizole metabolite, blocks the repolarizing K+ curren
20 t ventricular myocyte (NRVM) monolayers with astemizole or sertindole caused heterogeneous prolongati
21 e, exposure to the pharmacological chaperone astemizole, or specific mutations in the selectivity fil
22 inities of typical blockers (ie, dofetilide, astemizole, sertindole, and cisapride) were significantl
23                                              Astemizole stimulated autophagy, a hitherto unreported m
24                                              Astemizole undergoes extensive first-pass metabolism, an

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。